Mirion Technologies, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Mirion supplies radiation detection, measurement and monitoring products and services through its Medical and Industrial segments. The October 2021 business combination created “Successor” financial statements using acquisition accounting; comparisons with 2021 “Predecessor” results are not directly comparable because of purchase-accounting step-ups and a changed capital structure.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $175.8M | $180.0M | $339.0M | $346.2M |
| Gross profit / margin | $79.0M / 44.9% | $79.6M / 44.2% | $143.4M / 42.3% | $142.1M / 41.0% |
| Operating income (loss) | $(74.6)M | $4.7M | $(108.2)M | $(4.2)M |
| Net income (loss) | $(59.3)M | $(54.0)M | $(78.3)M | $(94.7)M |
| Net loss attributable to shareholders | $(58.6)M | $(53.9)M | $(76.3)M | $(94.6)M |
| Operating cash flow | Not presented by quarter | $28.0M | $33.7M | |
| Capital expenditures | Not presented by quarter | $15.3M | $13.9M | |
| Free cash flow (company-defined) | Not presented by quarter | $12.7M | $19.8M |
- Q2 revenue declined 2.3% year over year. Medical revenue rose to $66.8M from $52.1M, while Industrial revenue fell to $109.0M from $127.9M.
- Six-month revenue declined 2.1%; Medical grew to $126.9M from $103.6M, while Industrial decreased to $212.1M from $242.6M.
- Q2 included a $55.2M non-cash goodwill impairment in Industrial. A $19.6M warrant-liability fair-value gain partly offset the loss; the six-month gain was $39.5M.
- Adjusted EBITDA, a non-GAAP measure, was $42.6M in Q2 versus $49.9M; six-month adjusted EBITDA was $77.5M versus $89.9M. The company reported adjusted EPS of $0.13 for Q2 and $0.23 for the six-month period.
Balance sheet, debt and liquidity
- At June 30, cash and cash equivalents were $90.6M, total assets $2.92B, and current assets $450.2M versus current liabilities of $213.1M. Cash, cash equivalents and restricted cash totaled $92.0M.
- Third-party borrowings totaled $828.8M gross, including an $825.9M term loan; the balance-sheet carrying amount of non-current notes was $804.1M after current debt and financing costs. No revolver borrowings were outstanding; approximately $76.4M remained available after letters of credit.
- The term loan matures in October 2028 and had a 3.25% interest rate at June 30. The filing says the rate rose to 5.65% on July 1, 2022 and was expected to remain there for the rest of 2022. The company reported compliance with debt covenants at June 30.
- Management said operating cash flow, supplemented by debt arrangements, should provide adequate liquidity for the next 12 months. This is management’s assessment, not a guarantee.
Material changes, outlook and risks
- The Industrial segment was affected by Russia-Ukraine-related disruption, project timing, supply constraints and foreign exchange. A customer terminated a Finnish nuclear project involving a Russian state-owned entity; Mirion’s related backlog exposure was about $67M, with roughly 80% previously expected to be recognized over five years. Russian-related project backlog was $97.7M at June 30. The company reported delays and said customers could seek refunds of advance payments, though none had done so by the filing.
- The goodwill impairment followed the lost project and a lower estimated value for the RMS reporting unit. The impairment test used a 10.5% discount rate and 3.5% terminal growth assumption; $176.1M of RMS goodwill remained after the impairment and translation effects.
- Supply-chain disruption delayed components and revenue recognition and increased material and freight costs. Price increases offset part of the pressure; management warned of continuing margin risk.
- Currency movements reduced reported sales by an estimated 4.5% in Q2 and 3.5% for the first half. If June 30 exchange rates persisted, management estimated a roughly 3.7% full-year sales headwind versus the prior year. This is a sensitivity estimate, not formal earnings guidance.
- Backlog/remaining performance obligations were $692.7M at June 30, down from $747.5M at December 31, 2021. The company expected to recognize approximately 38% in fiscal 2022, 30% in 2023, 16% in 2024 and 8% in 2025, with the balance thereafter.
- Other risks include inflation, fixed-price contract execution, customer and government budget timing, supply-chain and cyber disruption, foreign exchange, interest rates, healthcare market conditions, and integration and public-company costs. Ordinary-course litigation was not expected by management to have a material effect, though outcomes remain uncertain. The company estimated $0.7M of additional restructuring charges, primarily within the next 12 months.
- No formal revenue or earnings outlook was provided in the supplied filing text. Management described Medical growth drivers and potential nuclear-market opportunities, while noting uncertainty around project timing and end-market conditions.
Investor verification points
- Verify whether Russian-related projects experience further cancellations, delays, or refund claims, and how these affect backlog conversion and cash flows.
- Assess the assumptions and potential further impairment risk for goodwill and acquired intangibles.
- Track the term-loan interest rate, debt service, covenant headroom and revolver availability as rates change.
- Monitor whether supply costs, foreign exchange and project timing continue to pressure Industrial revenue and consolidated margins.
- Reconcile reported GAAP losses and cash flow with management’s adjusted EBITDA, adjusted EPS and free-cash-flow measures; these non-GAAP measures exclude specified costs and may not be comparable with peers.
- Interpret year-over-year comparisons cautiously because the acquisition-method accounting and Successor/Predecessor reporting make periods less comparable.